RFK Jr.’s vaccine panel votes against thimerosal flu shots

A version of this article was first published in the CNBC’s healthy return bulletin, which brought the latest health news directly to your box. Subscribe here To get future prints.

A renewed vaccine consultants panel, with newly appointed vaccination suspects, voted against a long-targeted shot material that the anti-health movement has been targeted for a long time.

The group, called immune practices or ACIP Counseling Committee, voted against the Americans against influenza -containing influenza -containing influenza -containing influenza vaccines and timerosal. Health and Human Services Secretary Robert F. Kennedy Jr. was the first ACIP meeting since he broke the panel and stacked new members, including several well -known vaccine suspects.

Disease control and prevention centers should still sign this suggestion. If the agency does, the US will affect approximately 4 to 5% of the influenza vaccine supply.

According to CDC data, the country’s flu shots did not contain thimerosal in the last season of the virus. However, in the case of vaccination of an entire country, “Small percentages are important”, Dr. Sean O’leary told journalists last week.

If the flu shot containing several thimerosal was removed from the market,

O’Leary, “This will inevitably lead to the vaccination of fewer people, at least in the short term, perhaps longer in the longer and then more hospitalization and death.” He said.

The recommendation also strengthens false fears that have been going on for a long time that the substance can lead to developmental obstacles such as autism. Kennedy’s skepticism is a full circle with the vote of the panel: ten years before taking a step in the current role, published a searched book To remove Thimerosal from shooting and associate with developmental disorders.

“A very common anti -vaccination point around Thimerosal, so distrust in vaccines is a very clear strategy for bread.” He said.

Here is why thimerosal is important. It has been widely used for decades to prevent the growth of harmful bacteria in several drugs. For decades, more than 40 studies have not found a connection between Thimerosal and developmental delays.

However, as the use in approved vaccines, manufacturers fell sharply as they switched to single dose packaging, which does not require protectors. About 25 years ago, the Food and Pharmaceutical Administration, according to the CDC, asked producers to remove the substance very carefully from childhood vaccines.

“Thought, Mercury was a frightening sound word, and let’s just take it out, let’s make it a problem, O’learly said. Authorized, “Many studies are completely safe, it is not related to any neurodeficial disorder or other negative effects,” he added.

For adults, some very dose of influenza vaccines forms, Sanofi’s fluzon and Biotech Company CSL Seqirus, including two thimerosal.

A member of the panel. Cody Meissner, Dartmouth Geesel Medicine Faculty, a Professor of Pediatria, the use of multiple -substance bottles to deterrence for some groups can increase the cost of vaccination and limit access to the concern, he said. He also expressed his concerns about the message that the advice will send to other countries where the use of influenza vaccines is more common.

“This may limit the existence of influenza vaccine for some people.” He said.

Before the votes at the meeting, Lyn Redwood, a nurse practitioner who was interested in anti -vaccine organizations, was presented on the Timerosal in its flu vaccines. Between Redwood “Mercury mothers” He pushed Kennedy to join Mercury and Child Health. He also served as the President of Child Health Defense, which was an anti -vaccine organization established by Kennedy for years.

Feel free to send any clues, suggestions, story ideas and data to Annika. Annikakim.constantino@nbcuni.com.

Health Service Data Platform Arcadia, Private Capital Company Nordic Capital was purchased by companies announced Tuesday.

Arcadia converts health data into predictive information that payments and providers can use to improve the care of patients, to reduce costs, and to increase income. The company described the agreement with Nordic Capital as a “strategic partnership” in which the company will be the “majority owner” of Arcadia.

Michael Meucci, CEO of Arcadia, said that the study with Nordic Capital will allow Arcadia’s customer experience to improve its customer experience, expand artificial intelligence skills, explore new merger and purchasing opportunities, and increase growth in its basic segments, including value -based maintenance.

“It is very confirmed,” Meucci told CNBC in an interview. He continued: “To confirm that there are corporate investors with large caps that are determined to transform us as we are (USA?) Health services and global health services.”

Arcadia and Nordic Capital did not disclose the purchasing conditions. The agreement is expected to close in the second half of the year, but is still subject to regulatory approvals.

Meucci said that he knew the Nordic Capital team for several years and that the company watched Arcadia’s progress as a job. Arcadia Karlı made a successful purchase last year. Meucci said that the Scandinavian capital of these milestones helps make sure that the company is ready for the next growth stage.

Arcadia recently announced an external financing in 2023 when she announced a financing of $ 125 million from Vista credit partners. Arcadia said that Nordic Capital’s purchase served as an exit for previous investors.

“This partnership fits smoothly with Nordic Capital’s investment strategy and is excited to support Arcadia in the next stage,” Nordic Capital’s partner and partner Daniel Berglund said. He said.

Tripletree served as a financial advisor for Nordic Capital and advised Lazard Arcadia.

“This is the reinforcement of our mission that we have to change the cost of health services.” He said.

Read the entire version Here.

Feel free to send any clues, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.